We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Reckitt Benckiser Ireland Limited

7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Telephone: +353 1 468 9200
Fax: +353 1 468 9299

Summary of Product Characteristics last updated on medicines.ie: 03/03/2014
SPC Gaviscon Infant

Go to top of the page

Gaviscon Infant, Powder for Oral Suspension

Go to top of the page

Each unit dose sachet of 0.65 g powder contains 225 mg sodium alginate and 87.5 mg magnesium alginate.

Each dose contains 21 mg sodium

For a full list of excipients, see Section 6.1.

Go to top of the page

Powder for Oral Suspension.

Sachet containing an off-white powder.

Go to top of the page

Go to top of the page
4.1 Therapeutic indications

Gaviscon Infant helps to prevent gastric regurgitation in infants where competence of the cardiac sphincter has not been fully established.

The indications for use are gastric regurgitation, gastro-oesophageal reflux and reflux associated with hiatus hernia in infants and young children.

Go to top of the page
4.2 Posology and method of administration

Not to be used in premature infants or infants under one year except under medical supervision.

For oral use after mixing with water or milk feed.

Mix immediately before use as directed below:

Breast fed infants:

Under 4.5 kg (10 lb) - one dose.

Over 4.5 kg (10 lb) - two doses.

Add 5 mL of cooled, boiled water to the powder in a glass, mix to a smooth paste, add another 10 mL of the water and mix. Give after each feed using a spoon or feeding bottle.

Bottle fed infants:

Under 4.5 kg (10 lb) - one dose to be mixed into not less than 115 mL of each feed in the bottle and shaken well.

Over 4.5 kg (10 lb) - two doses to be mixed into not less than 225 mL of each feed in the bottle and shaken well.

Young children:

Two doses prepared as for breast fed infants, to be taken after each meal.

Not appropriate for adults or elderly.

Treatment should not be administered more than six times per 24 hours.

Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1

Contraindicated in cases of intestinal obstruction and in cases of established diarrhoea.

Not to be used except on a doctor or other healthcare professional's recommendation.

Not to be used in situations where excessive water loss is likely, e.g. fever, diarrhoea, vomiting or high room temperature. Not to be used in gastroenteritis where the appropriate treatment is rehydration with fluid replacement.

Not to be used when treating infants with known or suspected impairment of renal function as the sodium content (approximately 21 mg or 0.92 mmol per dose) may add to the risk of hypernatraemia.

Go to top of the page
4.4 Special warnings and precautions for use

Follow dosage instructions exactly to avoid an excessive amount of product per feed and the possible risk of hypernatraemia.

Hypernatraemia should be treated with oral fluids and monitoring of the infant's electrolytes. Severe cases should be treated by the cautious use of hypo-osmotic solutions.

There have been reports of abnormal stool consistency, e.g. diarrhoea or constipation, with use of this product. Significant or sustained changes in bowel habit should be investigated.

A medical review of the patient's condition should be undertaken seven days after initiating treatment or before if symptoms worsen.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Not to be used with thickening agents or infant milk preparations containing a thickening agent as this could lead to over-thickening of the stomach contents.

Go to top of the page
4.6 Fertility, pregnancy and lactation

Not appropriate.

Go to top of the page
4.7 Effects on ability to drive and use machines

Not appropriate.

Go to top of the page
4.8 Undesirable effects

Gaviscon Infant's mode of action is physical, resulting in a thickening of the gastric contents. An excessive concentration of Gaviscon Infant may lead to gastric distension.

Very Rare (<1/10,000): There have been reports of altered stool consistency, including symptoms of constipation and diarrhoea (See section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions preferably through the online reporting option accessible from the IMB homepage. A downloadable report form is also accessible from the IMB website, which may be completed manually and submitted to the IMB via 'freepost', in addition to the traditional post-paid 'yellow card' option.


Pharmacovigilance Section

Irish Medicines Board

Kevin O'Malley House

Earlsfort Centre

Earlsfort Terrace

Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.imb.ie

e-mail: imbpharmacovigilance@imb.ie

Go to top of the page
4.9 Overdose

Rare instances have occurred in which an intragastric mass has developed comprising Gaviscon Infant and milk proteins. Overdosage may have contributed to the development of such masses. The majority resolved spontaneously when the child was admitted to hospital, Gaviscon Infant was discontinued and a regime of adequate fluid intake and monitoring of fluid and electrolyte balance was installed. If spontaneous resolution of the mass does not occur, removal by surgical or endoscopic means may be required.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

The mode of action of Gaviscon Infant is physical. By reacting with acidic gastric contents to form a viscous gel it stabilises stomach activity so reducing the incidence of gastro-oesophageal reflux.

Go to top of the page
5.2 Pharmacokinetic properties

The mode of action of Gaviscon Infant is physical and does not depend on absorption into the systemic circulation.

Go to top of the page
5.3 Preclinical safety data

No preclinical findings of relevance to the prescriber have been reported.

Go to top of the page

Go to top of the page
6.1 List of excipient(s)

Mannitol (E421)

Colloidal silicon dioxide

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

Three years.

Go to top of the page
6.4 Special precautions for storage

Do not store above 30°C.

Go to top of the page
6.5 Nature and contents of container

A cardboard outer carton containing 30 unit dose sachets joined in pairs. The sachets are composed of paper (41 gsm), low density polyethylene (12 gsm), aluminium foil (21.6 gsm) with Surlyn (ethylene/methacrylic acid co-polymer neutralised with zinc) 1652 laminate (18 gsm). Two joined sachets enclosed in an outer cardboard wallet are also available.

Go to top of the page
6.6 Special precautions for disposal and other handling

Gaviscon Infant should be mixed with milk or water before taking. As the powder is sterile the sachet should not be opened until immediately before mixing.

Go to top of the page

Reckitt Benckiser Ireland Limited

7 Riverwalk

Citywest Business Campus

Dublin 24


Go to top of the page

PA 979/12/1

Go to top of the page

Date of first authorisation:

Date of last renewal:

12th July, 1991.

12th July, 2006.

Go to top of the page

July 2013.

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

   Magnesium Alginate
   Sodium Alginate